Genentech’s multiple sclerosis candidate fenebrutinib meets target in late-stage trial



Genentech’s multiple sclerosis candidate fenebrutinib meets target in late-stage trial



Source link

  • Related Posts

    Savannah Guthrie said, ‘We believe our mother is still there’

    Savannah Guthrie said, ‘We believe our mother is still there’ Source link

    Amentum misses initial and lower estimates; reaffirms the outlook for fiscal year 26

    Amentum misses initial and lower estimates; reaffirms the outlook for fiscal year 26 Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *